started · updated
Biogen emphasizes early diagnosis in neurology
At the 56th Congress of the Italian Society of Neurology in Florence, Biogen Medical Affairs Director Leila Khader identified early diagnosis as a strategic priority for healthcare innovation. Khader noted that the field of neurology is undergoing a transformation, moving from purely clinical classifications to molecular characterization through advancements in genetics, molecular biology, and digital technologies.
Biogen is focusing research and innovation on rare diseases, including spinal muscular atrophy, Friedreich's ataxia, and ALS associated with the Sod1 mutation. Khader highlighted that timely diagnosis is essential for altering the course of certain pathologies, citing neonatal screening for SMA as a successful example that allows children to access treatments early enough to modify the natural history of the disease.
Entities
Biogen · Florence · Italian Society of Neurology · Leila Khader